Actively Recruiting
Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
Led by National Taiwan University Hospital · Updated on 2025-12-23
120
Participants Needed
1
Research Sites
183 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
CONDITIONS
Official Title
Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult gastric cancer patients scheduled for gastrectomy
You will not qualify if you...
- Hepatic insufficiency
- Renal insufficiency
- Unable to tolerate oral or enteral feeding 7 days after gastrectomy
- Unable to undergo computed tomography
- Unable to wear wearable devices
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan, 100
Actively Recruiting
Research Team
J
Jin-Ming Wu, MD
CONTACT
M
Ming-Tsan Lin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here